featured
Secondary Cytoreduction Followed by Chemotherapy vs Chemotherapy Alone in Platinum-Sensitive Relapsed Ovarian Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Secondary Cytoreduction Followed by Chemotherapy Versus Chemotherapy Alone in Platinum-Sensitive Relapsed Ovarian Cancer (SOC-1): A Multicentre, Open-Label, Randomised, Phase 3 Trial
Lancet Oncol 2021 Mar 08;[EPub Ahead of Print], T Shi, J Zhu, Y Feng, D Tu, Y Zhang, P Zhang, H Jia, X Huang, Y Cai, S Yin, R Jiang, W Tian, W Gao, J Liu, H Yang, X Cheng, R ZangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.